Are Biopharma Patents Poised on the Post-Grant Chopping Block?

Publication
Article
BioPharm InternationalBioPharm International-10-15-2015
Volume 2015 eBook
Issue 2

This article examines trends in biopharma post-grant patent review and projects what the future holds in store.

BioPharm International

eBooks Volume 28, Issue 14  

Post-grant review of patents at the Patent Trial and Appeal Board (PTAB) has taken the intellectual property (IP) world by storm. Post-grant reviews allow anyone to challenge the validity of a patent far more quickly and cheaply than has ever before been possible. They have replaced the huge financial drain and business risk of traditional patent litigation with a rapid adjudication system that delivers certainty for a price comparable to a patent license fee.    Read this article and other articles in

BioPharm International

's 2015

The Future of Bioprocessing

eBook.

Articles in this issue
BP1015-Fluctuating.gif
Fluctuating Capacity and Demand Conditions in Biomanufacturing
BP1015-Cleaning.gif
Cleaning Validation for Biologics
BP1015-Automation.gif
Automation of Single-Use Systems
BP1015-Aseptic.gif
Aseptic Processing for Cytotherapy, Regenerative Medicine, and Tissue-Engineered Products
BP1015-Patent.gif
Are Biopharma Patents Poised on the Post-Grant Chopping Block?
BP1015-Innovations.gif
Innovations in Automation—High-Throughput Dynamic Light Scattering for Screening Biotherapeutic Formulations
BP1015-Raising-the-bar.gif
Raising the Bar for Biopharma Training
Recent Videos
Related Content
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Sanofi Invests €40 Million to Boost Antibody Production in France

Feliza Mirasol
November 21st 2024
Article

The investment will allow Sanofi to strengthen antibody bioproduction at its Lyon Gerland site in France.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Circio Forms Collaboration with Certest to Develop LNP Formulations

Feliza Mirasol
November 20th 2024
Article

Under the collaboration, the companies will create and test circVec DNA–LNP formulations with an eye toward potential therapeutic applications.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

SEKISUI Completes CDMO Capacity Expansion for CGMP Biopharma Manufacturing

Feliza Mirasol
November 19th 2024
Article

Under a £15.7 million (US$20.7 million) investment, SEKISUI has expanded its UK site for clinical-grade drug substance manufacturing.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Alentis Therapeutics Gains $181.4 Million Funding to Advance Anti-Claudin-1 ADCs in Solid Tumors

Feliza Mirasol
November 18th 2024
Article

With financing led by OrbiMed, Novo Holdings, and Jeito Capital, Alentis Therapeutics will develop a pipeline of Claudin-1-targeted ADCs to treat solid tumors.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Lecanemab Gets Nod from CHMP for Use in Early Alzheimer’s Disease

Felicity Thomas
November 15th 2024
Article

Eisai Europe and Biogen have received a positive opinion for the monoclonal antibody therapy to be used as a treatment of adult patients with early Alzheimer’s disease.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Avantor Geared for Biopharma Industry’s Future with Next-Generation Biotherapeutics

Feliza Mirasol
November 14th 2024
Article

Avantor executives discuss the future of the biopharmaceutical industry and the impact that a wave of next-generation biotherapeutics will bring.

© 2024 MJH Life Sciences

All rights reserved.